Trump administration authorises 172 million barrel SPR drawdown as 32 IEA nations coordinate record emergency oil release
Read More 5 minute read Pharma Industry News FDA extends deadline for Incyte’s Opzelura cream review in pediatric eczema following submission of new manufacturing data Incyte (NASDAQ: INCY) faces FDA review delay for Opzelura® cream in children aged 2–11 with eczema, following CMC data submission. Decision now due September 2025. byPallavi MadhirajuJune 25, 2025